Background: Multiple studies have examined the incidence of secondary primary malignancies (SPMs) in gastric cancer patients in Europe and Asia. This retrospective review was conducted to analyze risk of SPM in patients with gastric cancer diagnosed in the United States.
Geographic disparities exist in treatment modality as well (4) . Surgery remains the only potentially curative option (5) . Although multimodal treatment is the standard of care for bulky localized disease, adjuvant chemotherapy is typically employed in Asia, adjuvant chemoradiation in North America, and neoadjuvant chemotherapy in European and Australasian nations (4). Patients with advanced or recurrent disease typically receive systemic chemotherapy, as it provides a survival advantage over other treatments (6) .
Gastric cancer survivors are at risk for secondary primary malignancies (SPMs). This long-term complication was first described by Warren and Gates in 1932 (7) . Synchronous malignancies are defined as occurring with 6 months of the primary diagnosis, whereas metachronous tumors occur more than 6 months after the initial event. The risk of SPM is dependent on factors including patient age, cancer stage at diagnosis, and treatment modality (8) .
The risk of SPM in gastric cancer patients in the US is unknown. Given the global variations in gastric cancer incidence, treatment, and survival, we evaluated the risk of SPMs in adult gastric cancer patients in the US to determine if geographic disparities are present. In addition, increased awareness of SPMs will provide the framework for pilot intervention studies and the development of evidence-based guidelines for gastric cancer survivors.
MeThODOlOgY about seer Database
These data represent 14% of the US population, including the geographical areas of Atlanta, Connecticut, Detroit, Hawaii, Iowa, Los Angeles, New Mexico, rural Georgia, San FranciscoOakland, San Jose-Monterey, Seattle (Puget Sound region), Utah, and Alaska Natives (1). Comprehensive cancer data, including primary tumor site, staging, patient demographics, treatment, and survival from hospitals and cancer treatment facilities, are subjected to rigorous quality control studies, resulting in a mature database, with 98% case completeness.
study Population
We selected adult patients aged 18 years or more, diagnosed with gastric cancer as first primary malignancy from January 1992 to December 2012. Patients were followed from diagnosis to the date of last known vital status, death, or the last point of data collection. We excluded cases diagnosed at autopsy and those lost to follow-up. Using the Warren and Gates criteria (7) as modified by the NCI (9), SPM was defined as metachronous malignancy developing 6 months or more after an index gastric carcinoma.
Data analysis
We used SEER*stat software, Version 8.2.1 April 8, 2015 to calculate the standardized incidence ratio (SIR), absolute excess risk (AER), and confidence interval (CI) for SPM in patients, as previously diagnosed with gastric cancer. We analyzed that the risks of SPM by latency period (6-23 versus 24 months or more) and exposure to radiotherapy were determined.
The SIR, which is also known as the relative risk, is a relative measure of the strength of association between two cancers. It is calculated by dividing the observed incidence of SPM by the expected incidence of SPM [observed/expected (O/E) ratio] in the general population. AER is an absolute measure of the clinical burden of additional cancer per 10,000 occurrences in the population. It measures the actual number of excess events normalized to the number of person years observed [AER = (O − E) PY].
resUlTs
A total of 33,720 patients diagnosed with primary gastric cancer met the study criteria. Patient demographics are presented in Table 1 . A total of 1838 patients (5.26%) developed 2019 SPMs with an O/E ratio of 1.11 (CI = 1.06-1.16, p < 0.001; AER 18.16) ( Table 2) . A total of 1676 patients developed 1 SPM, and 162 developed 2 or more SPMs. The average age at diagnosis of SPM was 74 years (24-104 years). The median time from primary diagnosis to development of first SPM was 46.9 months (range 6-239 months). Significant excess risk was observed for gastrointestinal, biliary, pancreatic, and thyroid cancers. Significantly, decreased risk was observed for secondary melanoma, breast, and prostate cancer.
sPM and age
All patients had an increased risk of gastrointestinal second primary malignancies. On subgroup analysis, older patients had 
DiscUssiOn
There are currently more than 13 million cancer survivors in the US, with a projected increase to 18 million by 2022 (10) . Early diagnosis and development of new agents continue to improve cancer outcomes. Long-term morbidity and premature mortality may occur in survivors, as a result of comorbidities, treatment, or disease-related factors. In 2006, the Institute of Medicine report recommended the use of evidence-based guidelines to identify and manage the long-term effects of cancer, including surveillance for and prevention of recurrences and SPMs (11) . Studies such as this not only increase awareness of secondary malignancies but also provide valuable information that may be used to pilot interventions in care leading to improved outcomes for cancer survivors. SPMs are common in cancer patients with an overall cumulative incidence of 14% at 25 years of follow-up (12) .
Previously published literature has examined the incidence of SPMs in gastric cancer patients in Asia, Europe, and the Middle East. This is the first study to examine the incidence of SPM in gastric cancer patients in the US. Previous studies are inconsistent regarding the risks for SPM in gastric cancer, but our results are in agreement with the literature that suggests an increased risk for colon, liver, and pancreatic cancers 
